LBL-007
Advanced Solid Tumors
Key Facts
About LakeShore Biopharma
LakeShore Biopharma is a publicly traded company dedicated to addressing critical gaps in oncology and autoimmune disease treatment through a multi-faceted pipeline. The company has achieved key milestones by advancing multiple drug candidates into clinical development and securing strategic in-licensing agreements to bolster its portfolio. Its strategic direction involves progressing its lead assets through pivotal trials while exploring combination therapies and broader indications to maximize therapeutic impact and market potential.
View full company profileAbout LakeShore Biopharma
LakeShore Biopharma is a publicly traded company dedicated to addressing critical gaps in oncology and autoimmune disease treatment through a multi-faceted pipeline. The company has achieved key milestones by advancing multiple drug candidates into clinical development and securing strategic in-licensing agreements to bolster its portfolio. Its strategic direction involves progressing its lead assets through pivotal trials while exploring combination therapies and broader indications to maximize therapeutic impact and market potential.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| SHR-1701 | Jiangsu Hengrui Medicine | Phase 1 |
| BAY 1895344 | Bayer | Phase 1 |
| HS-10342 | Hansoh Pharma | Phase 1/2 |
| ANKTIVA® + M-ceNK | ImmunityBio | Phase 1 |
| DFTX-101 | Definium Therapeutics | Phase 1/2 |
| REC-617 | Recursion Pharmaceuticals | Phase 1/2 |
| ZW220 | Zymeworks | Preclinical |
| NX-1607 | Nurix Therapeutics | Phase 1a |
| IMA402 (TCR Bispecific) | Immatics | Phase 1 |
| IMA403 (TCR Bispecific) | Immatics | Pre-clinical |
| BCA101 | Bicara Therapeutics | Phase 1 |
| AN4005 | Adlai Nortye | Preclinical |